Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Expecting 2008 Restructuring Charges of $15.4M

NEW YORK (GenomeWeb News) – Affymetrix disclosed today in a filing with the US Securities and Exchange Commission that it expects to realize restructuring charges of $15.4 million for fiscal-year 2008 as part of its efforts to relocate the majority of its probe array manufacturing from West Sacramento, Calif., to Singapore.
Affy initially revealed its plans for the relocation in an SEC filing on Feb. 29. At the time, it said it expected to incur non-cash charges of around $12 million to $15 million related to the abandonment of certain manufacturing assets and approximately $500,000 related to employee severance in the first quarter of 2008.
According to the 10-Q filing today, the firm said of the $15.4 million in charges it now expects to incur, roughly $2.9 million will relate to employee severance and $12.5 million will relate to the abandonment of the manufacturing assets. Affy also said that depending on the rate at which it transfers operations to Singapore, it may incur additional expenses.
For the first quarter of 2008, Affy recognized approximately $1.4 million of charges related to employee severance and $12.5 million related to the manufacturing assets. The firm recently reported that its Q1 revenues were flat with the comparable period a year ago, excluding a $90 million settlement payment recognized during the quarter.
In a separate SEC filing today, Affy disclosed that investment advisor Fidelity Management & Research now owns 5,050,490 shares of the firm’s common stock, which represents a nearly 7.3 percent stake in Affy. Of that total amount, the Fidelity Growth Company Fund owns 4,403,190 shares, representing a stake of 6.34 percent in Affy as of April 30.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.